180 Life Sciences (NASDAQ:ATNF) Given Sell (E+) Rating at Weiss Ratings

180 Life Sciences (NASDAQ:ATNF)‘s stock had its “sell (e+)” rating reaffirmed by investment analysts at Weiss Ratings in a research note issued on Saturday,Weiss Ratings reports.

180 Life Sciences Stock Down 2.8 %

Shares of ATNF stock opened at $1.04 on Friday. 180 Life Sciences has a one year low of $0.66 and a one year high of $17.75. The company has a 50 day moving average price of $0.99 and a 200 day moving average price of $1.68.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in 180 Life Sciences stock. Rathbones Group PLC acquired a new position in shares of 180 Life Sciences Corp. (NASDAQ:ATNF) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund acquired 69,995 shares of the company’s stock, valued at approximately $127,000. Rathbones Group PLC owned 2.20% of 180 Life Sciences as of its most recent SEC filing. 4.07% of the stock is owned by institutional investors and hedge funds.

About 180 Life Sciences

180 Life Sciences Corp., a clinical stage biotechnology company, focuses on developing therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. The company product development platforms includes fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which has completed Phase IIb clinical trials that focuses on fibrosis and anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which are synthetic pharmaceutical grade molecules close or distant analogs of non-psychoactive cannabinoids, such as CBD for the treatment of inflammatory diseases and pain; and a7nAChR platform, an immune suppressive, which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor.